ACADIA PHARMACEUTICALS INC (ACAD) Q3 2025 10-Q Quarterly Report
ACADIA PHARMACEUTICALS INC (ACAD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
ACADIA PHARMACEUTICALS INC Q3 2025 10-Q Analysis
Risk Factors
- • New regulatory risk: January 2025 EU HTA Regulation No 2021/2282 requires joint clinical assessments impacting trofinetide pricing and reimbursement
- • Updated product acceptance risk: DAYBUE approved October 2024 in Canada; reliance on patient adherence and physician prescribing for Rett syndrome sales
ACADIA PHARMACEUTICALS INC Q3 2025 Quarterly FinancialsXBRL
Revenue
$279M
▲ +11.3% YoY▲ +5.3% QoQ
Net Income
$72M
▲ +119.1% YoY▲ +169.2% QoQ
Operating Margin
12.8%
▲ +20bp YoY▲ +60bp QoQ
Net Margin
25.8%
▲ +1268bp YoY▲ +1568bp QoQ
ROE
7.8%
Total Assets
$1.3B
EPS (Diluted)
$0.42
▲ +110.0% YoY▲ +162.5% QoQ
Operating Cash Flow
$74M
▲ +17.5% YoY▲ +16.2% QoQ
Source: XBRL data from ACADIA PHARMACEUTICALS INC Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on ACADIA PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.